Supplementary Material for Talbert and Yang et al. from Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities

Supplementary Material contains Supplementary Figures 1-5 and Supplementary Table 1. Supplementary Figure 1. MEK162 treatment prevents cancer-induced weight loss and muscle wasting. Supplementary Figure 2. Development of a MEK162 resistant C-26 tumor cell line. Supplementary Figure 3. MEK162 prevents cancer-induced weight loss and muscle wasting in part via a tumor extrinsic mechanism. Supplementary Figure 4. MEK162 prevents cancer-induced weight loss and muscle wasting when used in combination with buparlisib. Supplementary Figure 5. MEK162 and buparlisib modulate the immune system. Supplementary Table 1. Primer sequences used for real-time RT-PCR.